Rockefeller Financial Services Inc. continued to hold its stake in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,070 shares of the company’s stock at the end of the third quarter. Rockefeller Financial Services Inc.’s holdings in Eli Lilly and Company were worth $487,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. World Asset Management Inc increased its stake in shares of Eli Lilly and Company by 1.9% in the third quarter. World Asset Management Inc now owns 98,942 shares of the company’s stock worth $7,941,000 after buying an additional 1,851 shares during the last quarter. First Citizens Bank & Trust Co. increased its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares during the last quarter. Rothschild Asset Management Inc. increased its stake in shares of Eli Lilly and Company by 10.7% in the third quarter. Rothschild Asset Management Inc. now owns 16,449 shares of the company’s stock worth $1,320,000 after buying an additional 1,584 shares during the last quarter. Financial Architects Inc increased its stake in shares of Eli Lilly and Company by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the last quarter. Finally, Tarbox Group Inc. increased its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the last quarter. Hedge funds and other institutional investors own 73.90% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.32% during mid-day trading on Friday, hitting $77.40. 5,602,614 shares of the stock traded hands. The stock has a market cap of $81.87 billion, a price-to-earnings ratio of 33.67 and a beta of 0.25. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $84.80. The firm’s 50-day moving average is $71.60 and its 200-day moving average is $77.19.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and Company had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and Company’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 earnings per share. On average, analysts forecast that Eli Lilly and Company will post $3.54 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 10th. Investors of record on Wednesday, February 15th will be issued a $0.52 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $0.51. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Monday, February 13th. Eli Lilly and Company’s payout ratio is 88.70%.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of U.S. & international copyright law. The original version of this story can be viewed at http://www.dailypolitical.com/2017/01/13/eli-lilly-and-company-lly-position-held-by-rockefeller-financial-services-inc.html.

A number of brokerages have issued reports on LLY. Vetr downgraded shares of Eli Lilly and Company from a “hold” rating to a “sell” rating and set a $74.30 price objective on the stock. in a research note on Thursday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $85.00 price target (up from $82.00) on shares of Eli Lilly and Company in a research note on Wednesday, December 21st. Credit Suisse Group restated a “focus list” rating and issued a $87.00 price target on shares of Eli Lilly and Company in a research note on Monday, December 19th. Morgan Stanley upgraded shares of Eli Lilly and Company from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $73.00 to $82.00 in a research note on Friday, December 16th. Finally, BMO Capital Markets restated a “hold” rating and issued a $64.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $86.79.

In related news, insider Melissa S. Barnes sold 2,093 shares of the business’s stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $82.23, for a total value of $172,107.39. Following the transaction, the insider now directly owns 8,169 shares of the company’s stock, valued at approximately $671,736.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Friday, December 16th. The stock was sold at an average price of $72.59, for a total transaction of $14,518,000.00. Following the completion of the transaction, the insider now directly owns 125,649,408 shares in the company, valued at $9,120,890,526.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.